
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

SCHEDULE 13D

Under the Securities Exchange Act of 1934

(Amendment No. 3)*

Biomea Fusion, Inc.

(Name of Issuer)

Common Stock

(Title of Class of Securities)

09077A106

(CUSIP Number)

Neb Obradovic
Cormorant Asset Management, L.P., 200 Clarendon Street, 52nd Floor
Boston, MA, 02116
857-702-0386

(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

10/08/2025

(Date of Event Which Requires Filing of This Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. ☐

The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

SCHEDULE 13D

CUSIP No. 09077A106

Name of reporting person

1

Cormorant Global Healthcare Master Fund, LP

2

Check the appropriate box if a member of a Group (See Instructions)

	☐ (a)
	☒ (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	CAYMAN ISLANDS
	Sole Voting Power
7	0.00
Number of	Shared Voting Power
Shares	
Beneficially	8
Owned by	1,795,928.00
Each	Sole Dispositive Power
Reporting	9
Person	0.00
With:	Shared Dispositive Power
	10
	1,795,928.00
	Aggregate amount beneficially owned by each reporting person
11	1,795,928.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	2.59 %
	Type of Reporting Person (See Instructions)
14	PN

SCHEDULE 13D

CUSIP No. 09077A106

	Name of reporting person
1	Cormorant Global Healthcare GP, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
	Source of funds (See Instructions)
4	AF
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
Number of	7 Sole Voting Power

Shares	
Beneficially	0.00
Owned by	Shared Voting Power
Each	8
Reporting	1,795,928.00
Person	Sole Dispositive Power
With:	9
	0.00
	Shared Dispositive Power
	10
	1,795,928.00
	Aggregate amount beneficially owned by each reporting person
11	1,795,928.00
	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
12	☐
	Percent of class represented by amount in Row (11)
13	2.59 %
	Type of Reporting Person (See Instructions)
14	OO

SCHEDULE 13D

CUSIP No. 09077A106

	Name of reporting person
1	Cormorant Private Healthcare Fund III LP
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
	Source of funds (See Instructions)
4	WC
	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
5	☐
	Citizenship or place of organization
6	DELAWARE
	Sole Voting Power
7	0.00
	Shared Voting Power
Number of	8
Shares	1,717,232.00
Beneficially	Sole Dispositive Power
Owned by	9
Each	0.00
Reporting	Shared Dispositive Power
Person	10
With:	1,717,232.00
11	Aggregate amount beneficially owned by each reporting person

	1,717,232.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	2.48 %
14	Type of Reporting Person (See Instructions)
	PN

SCHEDULE 13D

CUSIP No. 09077A106

1	Name of reporting person
	Cormorant Private Healthcare GP III, LLC
	Check the appropriate box if a member of a Group (See Instructions)
2	☐ (a)
	☒ (b)
3	SEC use only
4	Source of funds (See Instructions)
	AF
5	Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)
	☐
6	Citizenship or place of organization
	DELAWARE
	Sole Voting Power
7	0.00
	Shared Voting Power
8	1,717,232.00
	Sole Dispositive Power
9	0.00
	Shared Dispositive Power
10	1,717,232.00
	Aggregate amount beneficially owned by each reporting person
11	1,717,232.00
12	Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)
	☐
13	Percent of class represented by amount in Row (11)
	2.48 %
14	Type of Reporting Person (See Instructions)
	OO

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Cormorant Asset Management, LP

Check the appropriate box if a member of a Group (See Instructions)

2

☐ (a)

☒ (b)

3

SEC use only

Source of funds (See Instructions)

4

AF

Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5

☐

Citizenship or place of organization

6

DELAWARE

Sole Voting Power

7

0.00

Shared Voting Power

8

3,570,872.00

Sole Dispositive Power

9

0.00

Shared Dispositive Power

10

3,570,872.00

Aggregate amount beneficially owned by each reporting person

11

3,570,872.00

Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

12

☐

Percent of class represented by amount in Row (11)

13

5.15 %

Type of Reporting Person (See Instructions)

14

PN

SCHEDULE 13D

CUSIP No. 09077A106

1

Name of reporting person

Chen Bihua

Check the appropriate box if a member of a Group (See Instructions)

2

☐ (a)

☒ (b)

3 SEC use only
Source of funds (See Instructions)

4 AF
Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

5 ☐
Citizenship or place of organization

6 UNITED STATES

7 Sole Voting Power

Number of Shares Beneficially Owned by Each Reporting Person With: 8 110,792.00
Shared Voting Power 3,570,872.00
Sole Dispositive Power 9 110,792.00
Shared Dispositive Power 10 3,570,872.00

11 Aggregate amount beneficially owned by each reporting person 3,681,664.00

12 Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

13 ☐
Percent of class represented by amount in Row (11) 5.31 %

14 Type of Reporting Person (See Instructions)
IN

SCHEDULE 13D

Item 1. Security and Issuer

Title of Class of Securities:

(a) Common Stock

Name of Issuer:

(b) Biomea Fusion, Inc.

Address of Issuer's Principal Executive Offices:

(c) 1599 INDUSTRIAL ROAD, SAN CARLOS, CALIFORNIA , 94070.

Item 1 Comment: This Amendment No. 3 to Schedule 13D (this "Amendment") relates to Common Stock of Biomea Fusion, Inc., a Delaware corporation (the "Issuer" or the "Company"). The address of the principal executive offices of the Issuer is 1599 Industrial Road, San Carlos, CA 94070. This Amendment is being filed by the Reporting Persons to amend the Schedule 13D that was filed on April 30, 2021, as amended by Amendment No. 1 filed on April 3, 2023, and Amendment No. 2 filed on July 22, 2025 (as so amended, the "Schedule 13D"). Unless otherwise indicated, all capitalized terms used herein but not defined herein shall have the same meaning as in the Schedule 13D.

Item 2. Identity and Background

(a) Cormorant Global Healthcare Master Fund, LP Cormorant Global Healthcare GP, LLC Cormorant Private Healthcare Fund III, LP Cormorant Private Healthcare GP III, LLC Cormorant Asset Management, LP Bihua Chen

(b) 200 Clarendon Street, 52nd Floor Boston, MA 02116

(f) Cormorant Global Healthcare Master Fund, LP - Cayman Islands Cormorant Global Healthcare GP, LLC - Delaware
Cormorant Private Healthcare Fund III, LP - Delaware Cormorant Private Healthcare GP III, LLC - Delaware
Cormorant Asset Management, LP - Delaware Bihua Chen - United States

- Item 5. Interest in Securities of the Issuer
- (a) See Items 7-13 of the cover page and Item 2.
- (b) See Items 7-13 of the cover page and Item 2. The percentages reported herein with respect to the Reporting Persons' holdings are calculated based upon (i) a statement in a Prospectus filed by the Issuer on October 7, 2025 that there would be 69,322,377 shares of Common Stock outstanding following the closing of a public offering described therein, and (ii) a statement in a Current Report on Form 8-K filed by the Issuer on October 7, 2025 reporting that the public offering was expected to close on October 8, 2025. The shares reported for Bihua Chen reflect shares of Common Stock that she has the right to receive within 60 days upon the exercise of stock options granted to her in her capacity as a director of the Issuer.
- (c) The Reporting Persons did not engage in any transactions in securities of the Issuer during the sixty day period prior to the filing of this Schedule 13D.
- (d) Not applicable.
- (e) Not applicable.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Cormorant Global Healthcare Master Fund, LP

Signature: /s/ CORMORANT GLOBAL HEALTHCARE
MASTER FUND, LP By: Cormorant Global
Healthcare GP, LLC, its General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 10/10/2025

Cormorant Global Healthcare GP, LLC

Signature: /s/ Bihua Chen

Name/Title: By: Bihua Chen, Managing Member

Date: 10/10/2025

Cormorant Private Healthcare Fund III LP

Signature: /s/ CORMORANT PRIVATE HEALTHCARE
FUND III, LP By: Cormorant Private Healthcare
GP III, LLC, its General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 10/10/2025

Cormorant Private Healthcare GP III, LLC

Signature: /s/ Bihua Chen

Name/Title: By: Bihua Chen, Managing Member

Date: 10/10/2025

Cormorant Asset Management, LP

Signature: /s/ CORMORANT ASSET MANAGEMENT, LP
By: Cormorant Asset Management GP, LLC, its
General Partner

Name/Title: By: Bihua Chen, Managing Member

Date: 10/10/2025

Chen Bihua

Signature: /s/ Bihua Chen

Name/Title: Bihua Chen

Date: 10/10/2025